Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CELLTOP Part II: AD-MSCs for Traumatic Spinal Cord Injury
NCT04520373Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Jun 2020
- Primary completion
- Jul 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous adipose-derived mesenchymal stromal cells in spinal cord injury (SCI) and paralysis (2 arms), sponsored by Mayo Clinic. Primary endpoint: American Spinal Injury Association Impairment Scale at 12 months. Started Jun 2020; status: active, not recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
spinal cord injury (SCI)paralysis
Beyond the preview
Go deeper on NCT04520373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520373.